Pyxis Oncology (PYXS) grants director Jakob Dupont 45,867 stock options

Rhea-AI Filing Summary

Pyxis Oncology director Jakob Dupont received a new stock option grant. The award covers 45,867 options to buy Common Stock at an exercise price of $1.36 per share, expiring on March 24, 2036. All of these options vest 100% on the first anniversary of the grant date, contingent on his continued service. Following this grant, Dupont holds 45,867 derivative securities, reflecting a routine, compensation-related equity award rather than an open‑market trade.

Insights

Equity compensation and governance analyst

Routine director option grant, no open‑market trading signal.

Pyxis Oncology granted director Jakob Dupont 45,867 stock options with a $1.36 exercise price, expiring in 2036. This is a compensation grant (code A), not a market purchase, so it mainly aligns incentives rather than indicating a trading view.

The options vest 100% on the first anniversary of the grant date, conditioned on continued service. That creates a one‑year retention and performance horizon for Dupont’s board role, but carries no immediate cash flow impact and is typical for director equity packages.

Because there are no same‑day sales, tax withholdings, or remaining option positions disclosed beyond this grant, the filing shows a straightforward award. Future company filings may add context on how such equity grants fit into the broader director compensation program.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dupont Jakob

(Last) (First) (Middle)

C/O PYXIS ONCOLOGY, INC.

321 HARRISON AVENUE, 11TH FL. SUITE 1

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pyxis Oncology, Inc. [ PYXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.36	03/24/2026		A		45,867		(1)	03/24/2036	Common Stock	45,867	$0	45,867	D

Explanation of Responses:

1. The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Jitendra Wadhane, Attorney-in-Fact for Jakob Dupont	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Pyxis Oncology (PYXS) director Jakob Dupont receive in this Form 4?

Director Jakob Dupont received a grant of 45,867 stock options to buy Pyxis Oncology common shares at an exercise price of $1.36. This is a compensation-related award, not an open-market purchase, and represents his reported derivative holdings after the grant.

Is Jakob Dupont buying or selling Pyxis Oncology (PYXS) stock in this filing?

No open-market buying or selling occurred. The Form 4 reports a stock option grant coded as an acquisition (A), meaning Dupont received 45,867 options as compensation. These options provide future purchase rights rather than an immediate stock transaction in the market.

What are the key terms of Jakob Dupont’s Pyxis Oncology (PYXS) stock options?

The grant covers 45,867 stock options with a $1.36 exercise price and an expiration date of March 24, 2036. Each option is exercisable into one share of Pyxis Oncology common stock, subject to vesting conditions tied to his continued board service.

When do Jakob Dupont’s Pyxis Oncology (PYXS) options vest?

All 45,867 options vest 100% on the first anniversary of the grant date, according to the footnote. Vesting is contingent on Dupont’s continued service with Pyxis Oncology through that vesting date, a common structure for director equity incentives.

How many Pyxis Oncology (PYXS) derivative securities does Jakob Dupont hold after this grant?

After the reported transaction, Dupont holds 45,867 derivative securities, all from this stock option grant. The filing lists this total as his holdings following the transaction, with no additional remaining option positions disclosed in the derivative summary section.

Does this Pyxis Oncology (PYXS) Form 4 indicate a strong trading signal from the director?

This filing mainly reflects routine equity compensation, not a trading signal. The transaction is a grant of 45,867 stock options, with no shares bought or sold in the market. Such awards are typically used to align director incentives with shareholder interests over time.